Anthony Petrone
Stock Analyst at Mizuho
(4.05)
# 524
Out of 5,131 analysts
215
Total ratings
54.43%
Success rate
10.96%
Average return
Main Sectors:
Stocks Rated by Anthony Petrone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Outperform | $78 → $90 | $70.02 | +28.53% | 4 | Feb 13, 2026 | |
| INSP Inspire Medical Systems | Maintains: Outperform | $130 → $85 | $59.76 | +42.24% | 8 | Feb 12, 2026 | |
| HAE Haemonetics | Maintains: Outperform | $90 → $80 | $57.76 | +38.50% | 17 | Feb 6, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $140 → $115 | $74.73 | +53.89% | 9 | Feb 5, 2026 | |
| EXAS Exact Sciences | Downgrades: Neutral | $85 → $105 | $103.24 | +1.70% | 2 | Jan 20, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $18 → $21 | $18.96 | +10.76% | 2 | Dec 17, 2025 | |
| MDXG MiMedx Group | Maintains: Outperform | $12 → $10 | $5.12 | +95.31% | 5 | Dec 17, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $70 → $72 | $65.82 | +9.39% | 10 | Dec 17, 2025 | |
| LNTH Lantheus Holdings | Maintains: Outperform | $60 → $72 | $69.38 | +3.78% | 7 | Dec 17, 2025 | |
| GH Guardant Health | Maintains: Outperform | $100 → $120 | $104.85 | +14.45% | 4 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $90 | $74.60 | +20.64% | 9 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $100 | $82.99 | +20.50% | 16 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $33.24 | +20.34% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $100 | $79.20 | +26.26% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $300 | $252.55 | +18.79% | 18 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $100 | $75.87 | +31.80% | 10 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $70 → $78 | $75.06 | +3.92% | 10 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $135 | $103.75 | +30.12% | 9 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $140 → $135 | $112.68 | +19.81% | 6 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $16.10 | +11.80% | 8 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $98 → $100 | $99.49 | +0.51% | 7 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $12 | $10.17 | +17.99% | 3 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $175 | $109.47 | +59.86% | 10 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $7.51 | +432.62% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $58 | $60.78 | -4.57% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $14 | $16.09 | -12.99% | 6 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $105 | $80.34 | +30.69% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $390 | $485.84 | -19.73% | 6 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $63 → $67 | $87.71 | -23.61% | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $175 | $96.45 | +81.44% | 3 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $25 | $13.52 | +84.91% | 3 | May 13, 2020 |
DexCom
Feb 13, 2026
Maintains: Outperform
Price Target: $78 → $90
Current: $70.02
Upside: +28.53%
Inspire Medical Systems
Feb 12, 2026
Maintains: Outperform
Price Target: $130 → $85
Current: $59.76
Upside: +42.24%
Haemonetics
Feb 6, 2026
Maintains: Outperform
Price Target: $90 → $80
Current: $57.76
Upside: +38.50%
Boston Scientific
Feb 5, 2026
Maintains: Outperform
Price Target: $140 → $115
Current: $74.73
Upside: +53.89%
Exact Sciences
Jan 20, 2026
Downgrades: Neutral
Price Target: $85 → $105
Current: $103.24
Upside: +1.70%
Tandem Diabetes Care
Dec 17, 2025
Maintains: Neutral
Price Target: $18 → $21
Current: $18.96
Upside: +10.76%
MiMedx Group
Dec 17, 2025
Maintains: Outperform
Price Target: $12 → $10
Current: $5.12
Upside: +95.31%
LivaNova
Dec 17, 2025
Maintains: Outperform
Price Target: $70 → $72
Current: $65.82
Upside: +9.39%
Lantheus Holdings
Dec 17, 2025
Maintains: Outperform
Price Target: $60 → $72
Current: $69.38
Upside: +3.78%
Guardant Health
Dec 17, 2025
Maintains: Outperform
Price Target: $100 → $120
Current: $104.85
Upside: +14.45%
Dec 17, 2025
Maintains: Outperform
Price Target: $85 → $90
Current: $74.60
Upside: +20.64%
Dec 5, 2025
Maintains: Outperform
Price Target: $85 → $100
Current: $82.99
Upside: +20.50%
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $33.24
Upside: +20.34%
Nov 11, 2025
Maintains: Outperform
Price Target: $110 → $100
Current: $79.20
Upside: +26.26%
Oct 31, 2025
Maintains: Outperform
Price Target: $310 → $300
Current: $252.55
Upside: +18.79%
Oct 31, 2025
Maintains: Outperform
Price Target: $90 → $100
Current: $75.87
Upside: +31.80%
Oct 23, 2025
Downgrades: Neutral
Price Target: $70 → $78
Current: $75.06
Upside: +3.92%
Aug 1, 2025
Maintains: Neutral
Price Target: $130 → $135
Current: $103.75
Upside: +30.12%
Jul 18, 2025
Maintains: Neutral
Price Target: $140 → $135
Current: $112.68
Upside: +19.81%
Jul 16, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $16.10
Upside: +11.80%
Jul 16, 2025
Maintains: Outperform
Price Target: $98 → $100
Current: $99.49
Upside: +0.51%
Jul 16, 2025
Maintains: Neutral
Price Target: $13 → $12
Current: $10.17
Upside: +17.99%
Apr 16, 2025
Maintains: Outperform
Price Target: $200 → $175
Current: $109.47
Upside: +59.86%
Apr 10, 2025
Initiates: Outperform
Price Target: $40
Current: $7.51
Upside: +432.62%
Mar 6, 2025
Maintains: Buy
Price Target: $54 → $58
Current: $60.78
Upside: -4.57%
Jun 20, 2024
Maintains: Buy
Price Target: $12 → $14
Current: $16.09
Upside: -12.99%
May 1, 2024
Maintains: Buy
Price Target: $110 → $105
Current: $80.34
Upside: +30.69%
Jan 25, 2024
Maintains: Neutral
Price Target: $350 → $390
Current: $485.84
Upside: -19.73%
Aug 3, 2023
Downgrades: Hold
Price Target: $63 → $67
Current: $87.71
Upside: -23.61%
Nov 5, 2021
Maintains: Buy
Price Target: $200 → $175
Current: $96.45
Upside: +81.44%
May 13, 2020
Maintains: Hold
Price Target: $30 → $25
Current: $13.52
Upside: +84.91%